For millions of Americans living with obesity, the arrival of GLP-1 receptor agonists has felt like a medical turning point. These medications—including household names like Wegovy and Zepbound—have demonstrated a profound ability to reduce weight and lower the risk of cardiovascular disease. Yet, for those relying on public insurance, the clinical promise of these drugs has long been stalled by a stark financial and legal wall.
Under current federal law, Medicare is strictly prohibited from covering medications used specifically for weight loss. While Medicaid offers states the flexibility to provide coverage, the high cost of these drugs has led most to opt out; as of January 2026, only 13 states provided such coverage. This has left a vast population of low- and modest-income seniors and disabled adults facing a prohibitive choice: pay thousands of dollars out-of-pocket or go without treatment.
To address this gap, the Trump administration and the Centers for Medicare & Medicaid Services (CMS) are implementing a series of temporary “demonstration” programs. These include the Medicare GLP-1 Bridge and the BALANCE Model. While these initiatives aim to lower costs and expand access, they are complex, temporary, and—in the case of Medicare—facing significant implementation hurdles.
As a physician, I have seen how the intersection of clinical need and insurance bureaucracy can derail patient health. The current strategy by CMS represents a pragmatic attempt to bypass statutory bans through temporary pilots, but for the patient, the details of who qualifies and for how long are critical.
The Medicare GLP-1 Bridge: A Temporary Lifeline
Because CMS cannot legally change Medicare’s ban on obesity drugs without an act of Congress, it has created the Medicare GLP-1 Bridge. Here’s a nationwide demonstration program that operates entirely separate from the standard Medicare Part D prescription drug benefit. By keeping the program separate, CMS can provide coverage without requiring Part D insurance plans to take on the financial risk.
Starting July 1, 2026 and extending through December 31, 2027, eligible Part D beneficiaries can access select GLP-1s for obesity at a fixed copayment of $50 per month. The drugs included in this bridge are all formulations of Foundayo and Wegovy, as well as the KwikPen formulation of Zepbound.
To qualify, patients must have a provider submit a prior authorization request attesting that the drug is being used for weight reduction and maintenance, and that the patient meets specific BMI and clinical diagnostic criteria. Manufacturers have agreed to provide these drugs at a negotiated net price of $245 per month supply.
However, there are important caveats for beneficiaries. Because the Bridge operates outside of Part D, the $50 monthly copayment does not count toward a patient’s annual deductible or the out-of-pocket maximum. Those enrolled in the Low-Income Subsidy (LIS) program will find that their usual cost-sharing subsidies do not apply here, meaning the $50 fee must be paid in full, which may still be a barrier for the most vulnerable patients.
The BALANCE Model: Medicaid Rollout and Medicare Delays
While the Bridge is a short-term fix, the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) was designed as a more comprehensive, long-term strategy. The model combines discounted drug pricing with free lifestyle support programs—such as nutritional counseling and physical activity guidance—provided by the manufacturers to improve medication adherence and effectiveness.
The rollout of the BALANCE Model is split between the two major public programs:
- For Medicaid: The model is moving forward. Implementation begins on a rolling basis from May 1, 2026, through January 1, 2027, and is scheduled to run through December 2031. Participating states will gain access to discounted GLP-1 pricing through supplemental rebate agreements.
- For Medicare: The model has hit a wall. CMS originally intended to launch BALANCE for Medicare Part D in 2027, but it has been indefinitely delayed. The agency failed to reach a “critical mass” of participating Part D plan sponsors—specifically an 80% participation threshold. Reports indicate that major plan sponsors were reluctant to participate due to the projected costs.
The delay in the BALANCE Model is why the Medicare GLP-1 Bridge was extended through the end of 2027. CMS is currently collecting more utilization data to convince Part D sponsors to join a future version of the model.
| Feature | Medicare GLP-1 Bridge | BALANCE Model (Medicaid) |
|---|---|---|
| Timeline | July 2026 – Dec 2027 | May 2026 – Dec 2031 |
| Patient Cost | $50 Monthly Copay | Nominal Medicaid Copays |
| Drug Access | Select GLP-1s (Obesity only) | Broad GLP-1s (Obesity & others) |
| Additional Support | Medication only | Free Lifestyle Support Programs |
The High Cost of Access
The reluctance of private Part D plans to join the BALANCE Model stems from the staggering projected costs. Estimates suggest that covering obesity drugs under Medicare Part D could cost between $25 billion and $35 billion over a decade. For Medicaid, the estimated cost is $15 billion, with the federal government covering the bulk of that expense.
From a public health perspective, the argument for these costs is that obesity is a primary driver of other expensive conditions, such as type 2 diabetes, sleep apnea, and heart disease. However, there is currently little short-term evidence to suggest that the cost of the drugs will be offset by a reduction in other healthcare spending within the timeframe of these pilots.
For the patient, the biggest risk is the “coverage cliff.” If the Medicare GLP-1 Bridge ends in December 2027 and the BALANCE Model is still not implemented for Medicare, thousands of patients who have stabilized their health on these medications could suddenly lose access, potentially leading to rapid weight regain and the return of comorbid conditions.
Disclaimer: This article is for informational purposes only and does not constitute medical or financial advice. Patients should consult with their healthcare provider and insurance representative to determine eligibility and coverage for specific medications.
The next critical milestone for these programs will be the May 1, 2026, launch of the BALANCE Model for participating state Medicaid programs. This rollout will provide the first real-world data on how these discounted pricing structures and lifestyle supports function at scale, which may ultimately determine if the Medicare version of the model ever becomes viable.
Do you or a loved one rely on GLP-1s through Medicare or Medicaid? Share your experience in the comments or share this guide with someone navigating these coverage changes.
